Biotech

Merck’s Women’s Health Spinoff Organon Announces the Acquisition of Maternal Health Company Alydia Health

Merck and Alydia Health have announced that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications…

Bonafide Brings Innovation to the Menopause Space With New Non-Drug Solutions

Bonafide, the women’s healthcare brand with a unique research-first approach to non-drug products, is at the forefront of modernizing menopause. Since its inception in 2018, the Company has invested millions of dollars on clinical research, conducted at least 3-4 studies per year, and brought one new product to market every 12 months. To date, more than 70,000 women love and trust Bonafide’s…

Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring for the Treatment of Vasomotor Symptoms and Genitourinary Syndrome Associated with Menopause

Daré, a leader in women’s health innovation has recently announced completion of patient recruitment in its Phase 1 clinical trial of DARE-HRT1 being conducted through its wholly owned subsidiary in Australia. DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period. It is being developed for the treatment of vasomotor symptoms (VMS)…

Mayne Pharma Launches A Generic Version of ORTH-CEPT, an Oral Contraceptive, in the U.S.

Mayne Pharma has announced the commercial launch of a generic version of ORTHO-CEPT (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US. This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN 24 FE, ORTHO CYCLEN and ORTHO TRI-CYCLEN. According to IQVIA, the annual US market sales for the four products were…

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

Ferring Pharmaceuticals, Rebiotix, a Ferring Company, and MyBiotics Pharma today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age linked to increased risk of miscarriage and complications for pregnancy and fertility. The collaboration is an important step forward in harnessing the power of the human microbiome in this area…

Veteran Biotech Executive Elizabeth Cormier-May Joins Women’s Health Startup Mammogen as the Company’s New CEO

Mammogen, a women’s health startup born at the intersection of data, technology and science has announced the appointment of Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. She will begin her new role on March 1st, 2021.   In her new role, Cormier-May will lead efforts to develop, validate and commercialize the company’s flagship liquid biopsy program for…

Vizgen Announces U.S. Accelerator Lab to Advance Pharma R&D

Vizgen, a life sciences company developing the next generation of in situ single-cell genomics, today announced the launch of its Pharma Accelerator Lab in response to high demand from leading pharmaceutical companies who are increasingly turning to single-cell and spatial transcriptomics solutions to accelerate their drug development pipelines. “Today’s pharma R&D leaders are benefiting from spatial omics approaches that unlock unprecedented insight…

The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi Contraceptive Gel

Evofem Biosciences has announced that the U.S. Department of Veterans Affairs has awarded the Company a contract for the purchase of Phexxi for a five-year period beginning December 15, 2020. Saundra Pelletier, CEO of Evofem Biosciences, said, “This award is an important milestone in our ongoing effort to create the broadest access to Phexxi for all patients.  We have achieved coverage for 55% of…